Child’s play


Atoms and Molecules – a child’s guide to chemistry
Adam Smith
2012 | 14pp | £1.98 (Kindle only)
AISN B008EX6HM0
Reviewed by Richard Kidd and family
http://amzn.to/Y5ptd6

Clearly a book designed to ‘introduce infants and toddlers to the shapes and sounds of chemistry’ needed live testing:

Susan (age 7):

It starts off simple, but then it just gets so complicated I don’t understand it. There are some tricky words – I do not know what a three dimensional wave is, so how will anyone younger? Younger ones will also not know what methane, ethanol, DNA or a lipid is. Some of the letters next to the drawings don’t mean anything.

Helen (age 10):

This book is quite hard to understand nearer the end. How are 6 year olds meant to understand a three dimensional wave? I am a 10 year old and I don’t understand what it is. I also want to know why there are random letters around the pictures; perhaps they are atom names? I like how the pictures are simple and look rather spectacular.

Richard (age 47):

It’s tricky to work out the age this is aimed at – there are only a few pages, but a third of the way through the terms ramp up to GCSE and A-level concepts. The child’s pictures were just enough to hold my two year old’s interest, but the older ones were a bit baffled.

Purchase Atoms and Molecules for the Kindle on Amazon.co.uk


Related Content

What is a bond?

30 January 2014 Premium contentFeature

news image

There’s more to bonding than covalent, ionic and the lines we draw between atoms on paper. Philip Ball takes on the expandi...

What we mean when we talk about bonds

29 January 2015 Comments

news image

Santiago Alvarez delves into the debates and disagreements that surround one of chemistry's most fundamental concepts

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent